Membranous glomerulonephritis, psoriasis and etanercept. A chance or causal association?;Glomerulonefritis membranosa, psoriasis y etanercept. ¿Asociación casual o causal?

Nefrologia

Volumn 32, Issue 2, 2012, Pages 228-232

  Florit, Enrique A ^a   Úbeda Aranda, Isabel ^a   Delgado Conde, Pablo ^a   Rodríguez Cubillo, Beatriz ^a   Monzón Vázquez, Tania ^a   de la Flor Merino, José C ^a   Valga Amado, Francisco ^a   Barrientos Guzmán, Alberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

C1q deposits; Etanercept; Membranous nephropathy; Proteinuria; Psoriasis; Tumor necrosis factor alfa (TNF alpha)

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PSORIASIS;

ADULT; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84864417515     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Jan.10946     Document Type: Article

References (43)

1. Singh NP, Prakash A, Kubba S, Ganguli A, Singh AK, Sikdar S, et al. Psoriatic nephropathy-does an entity exist? Ren Fail 2005;27(1):123-7.
2. Heuvels J, Maximus A, Bosmans JL, Lambert J, De Broe ME. Renal abnormalities in psoriatic patients: a review. Nephron 1999;82 (1):1-6.
3. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al.; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349(21):2014-22.
4. Zachariae H, Grunnet E, Sogaard H. Accidental kidney biopsies in psoriasis. Br J Dermatol 1976;94(6):655-7.
5. Grcevska L, Polenakovi M, Ferluga D, Vizjak A, Stavrić G. Membranous nephropathy with severe tubulointerstitial and vascular changes in a patient with psoriatic arthritis treated with non-steroidal anti-inflammatory drugs. Clin Nephrol 1993;39(5):250-3.
6. Kaji T, Tsukada Y, Shimada A, Miyamoto K, Yoshida M, Yano S, et al. Membranous nephropathy associated with psoriasis vulgaris. Clin Nephrol 1994;42(1):63-4.
7. Tani Y, Yamamoto T, Shimazaki K, Kawai K, Nishide K, Abe T. [A case of psoriasis vulgaris associated with nephrotic syndrome histologically overlapping of membranous nephropathy and IgA nephropathy]. Nippon Naika Gakkai Zasshi 1988;77(7):1081-4.
8. Yamaji H, Shikata K, Wada J, Hayashi Y, Ikeda S, Makino H. A case of membranous nephropathy associated with psoriasis vulgaris. Nephron 1998;80(1):111-2.
9. Zadrazil J, Tichy T, Horák P, Nikorjaková I, Zíma P, Krejcí K, et al. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of 'psoriatic nephropathy'. J Nephrol 2006;19(3):382-6.
10. Cassano N, Vestita M, Panaro M, Carbonara M, Vena GA. Renal function in psoriasis patients. Eur J Dermatol 2011;21(2):264-5.
11. Kaftan O, Kaftan B, Toppare MF, Eksioglu M. Renal involvement in psoriasis. Dermatology 1996;192(2):189-90.
12. Piscator M. Early detection of tubular dysfunction. Kidney Int Suppl 1991;34:S15-7.
13. Szepietowski JC, Szepietowski T. Is renal function altered in patients with psoriasis vulgaris?-A short review. J Dermatol 2000; 27(9):569-72.
14. Dervisoglu E, Akturk AS, Yildiz K, Kiran R, Yilmaz A. The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol 2011 Apr 20. [Epub ahead of print].
15. Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A. Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology 1992;185(2):93-5.
16. Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol 1998;18 (5):425-9.
17. Guilhou JJ, Clot J, Meynadier J, Lapinski H. Immunological aspects of psoriasis I Immunoglobulins and anti-IgG factors. Br J Dermatol 1976;94(5):501-7.
18. Sakemi T, Hayashida R, Ikeda Y, Baba N, Nishihara G, Kohda H. Membranous glomerulonephropathy associated with psoriasis vulgaris. Nephron 1996;72(2):351-2.
19. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 2010;56(1):157-67.
20. Lionaki S, Siamopoulos K, Theodorou I, Papadimitraki E, Bertsias G, Boumpas D, et al. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 2009;24(7):2144-50.
21. Neale TJ, Rüger BM, Macaulay H, Dunbar PR, Hasan Q, Bourke A, et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995;146(6):1444-54.
22. Nakajima M, Kawahara S, Sakagami Y, Takagawa K, Akazawa H, Kamitsuji H, et al. Immunogold labelling of cytokines in glomeruli in children with various renal diseases. Nephron 1999;83(2):132-8.
23. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ. Circulating factors in sera or peripheral blood mononuclear cells in patients with membranous nephropathy or diabetic nephropathy. J Korean Med Sci 1997;12(6):539-44.
24. Zhu LJ, Yang X, Yu XQ. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:465898.
25. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005;20(7):1400-6.
26. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008;10 (1):202.
27. Ferraccioli G. [Biologic therapy with anti-TNFalpha in rheumathoid atrhritis]. Reumatismo 2005;57(4 Suppl):17-21.
28. Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs 2011;13(3):161-73.
29. Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31(10):1955-8.
30. Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004;62 (3):234-8.
31. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359(9306):579-80.
32. Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73(6):710-3.
33. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126(1):13-30.
34. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005;34(5 Suppl1):12-8.
35. Wenderfer SE, Swinford RD, Braun MC. C1q nephropathy in the pediatric population: pathology and pathogenesis. Pediatr Nephrol 2010;25(8):1385-96.
36. Müller W, Hanauske-Abel H, Loos M. Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol 1978;121(4):1578-84.
37. Vizjak A, Ferluga D, Rozic M, Hvala A, Lindic J, Levart TK, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol 2008;19(11):2237-44.
38. Davenport A, Maciver AG, Mackenzie JC. C1q nephropathy: do C1q deposits have any prognostic significance in the nephrotic syndrome? Nephrol Dial Transplant. 1992;7(5):391-6.
39. Mubarak M, Kazi JI, Shakeel S, Lanewala A, Hashmi S, Akhter F. Clinicopathologic characteristics and steroid response of IgM nephropathy in children presenting with idiopathic nephrotic syndrome. APMIS 2011;119(3):180-6.
40. Kazi JI, Mubarak M, Malik SS. Clinicopathologic study of IgM nephropathy in children presenting with idiopathic nephrotic syndrome in Pakistan. J Pak Med Assoc 2010;60(10):878-9.
41. Meyer OC, Nicaise-Roland P, Cadoudal N, Grootenboer-Mignot S, Palazzo E, Hayem G, et al. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 2009;11(3):R87.
42. Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Frémeaux-Bacchi V, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006;21(11):3115-21.
43. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1qfixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011;91(3):342-7.